Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Single-blind, Multi-center, Randomization, Phase Ⅱ Study to Evaluate Efficacy and Safety of Cellgram-ED (Autologous Bone Marrow-derived Mesenchymal Stem Cells) in Erectile Dysfunction Patients With Following Radical Prostatectomy

Next Previous
X
Search
Trial Profile

An Single-blind, Multi-center, Randomization, Phase Ⅱ Study to Evaluate Efficacy and Safety of Cellgram-ED (Autologous Bone Marrow-derived Mesenchymal Stem Cells) in Erectile Dysfunction Patients With Following Radical Prostatectomy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous mesenchymal stem cell therapy Pharmicell (Primary)
  • Indications Erectile dysfunction
  • Focus Therapeutic Use
  • Acronyms Cellgram-ED
  • Sponsors Pharmicell

    • Most Recent Events

    • 10 Apr 2024 Planned End Date changed from 31 Oct 2023 to 31 Jan 2026.
    • 10 Apr 2024 Planned primary completion date changed from 31 Oct 2023 to 31 Dec 2025.
    • 07 Nov 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Oct 2020).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top